Shield Therapeutics (AIM: STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency with Feraccru®. Following IPO and EU approval of Feraccru, both in February 2016, STX has made good progress with its clinical and commercial strategy, most recently demonstrating in a phase 3 trial that oral Feraccru is as effective as intravenous iron. Management has secured commercialisation agreements and is now awaiting an FDA decision in 3Q’19. The remaining risks lie in US approval and in successful execution of commercialisation.
If you'd like to be introduced to the team at Shield Therapeutics Plc, get in touch.Request a meeting